Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Long-Term Investments (2018 - 2023)

Historic Long-Term Investments for Rocket Pharmaceuticals (RCKT) over the last 3 years, with Q4 2023 value amounting to $34.3 million.

  • Rocket Pharmaceuticals' Long-Term Investments fell 2069.51% to $34.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $34.3 million, marking a year-over-year decrease of 2069.51%. This contributed to the annual value of $34.3 million for FY2023, which is 2069.51% down from last year.
  • According to the latest figures from Q4 2023, Rocket Pharmaceuticals' Long-Term Investments is $34.3 million, which was down 2069.51% from $29.0 million recorded in Q1 2023.
  • Rocket Pharmaceuticals' 5-year Long-Term Investments high stood at $43.3 million for Q4 2022, and its period low was $29.0 million during Q1 2023.